Dual Functions of the AML1/Evi-1 Chimeric Protein in the Mechanism of Leukemogenesis in t(3;21) Leukemias
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
The chromosomal translocation t(3;21)(q26;q22), which is found in blastic crisis in chronic myelogenous leukemias and myelodysplastic syndrome-derived leukemias, produces AML1/Evi-1 chimeric transcription factor and is thought to play important roles in acute leukemic transformation of hemopoietic stem cells. We report here the functional analyses of AML1/Evi-1. It was revealed that AML1/Evi-1 itself does not alter the transactivation level through mouse polyomavirus enhancer-binding protein 2 (PEBP2; PEA2) sites (binding site of AML1) but dominantly suppresses the transactivation by intact AML1, which is assumed to be a stimulator of myeloid cell differentiation. DNA-binding competition is a putative mechanism of such dominant negative effects of AML1/Evi-1 because it binds to PEBP2 sites with higher affinity than AML1 does. Furthermore, AML1/Evi-1 stimulated c-fos promoter transactivation and increased AP-1 activity, as Evi-1 (which is not normally expressed in hemopoietic cells) did. Experiments using deletion mutants of AML1/Evi-1 showed that these two functions are mutually independent because the dominant negative effects on intact AML1 and the stimulation of AP-1 activity are dependent on the runt domain (DNA-binding domain of AML1) and the zinc finger domain near the C terminus, respectively. Furthermore, we showed that AML1/Evi-1 blocks granulocytic differentiation, otherwise induced by granulocyte colony-stimulating factor, of 32Dcl3 myeloid cells. It was also suggested that both AML1-derived and Evi-1-derived portions of the fusion protein play crucial roles in this differentiation block. We conclude that the leukemic cell transformation in t(3;21) leukemias is probably caused by these dual functions of AML1/Evi-1 chimeric protein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Miyoshi, H., Shimizu, K., Kozu, T., Maseki, N., Kaneko, Y., & Ohki, M. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10431 · Cited by 872 · cited 4×
“It is intriguing to hypothesize that AML1/MTG8 (ETO) and PEBP2b (CBFB)/SMMHC also exert dominant negative effects on AML1.”
BackgroundInfluentialFusion Between Transcription Factor CBFβ/PEBP2β and a Myosin Heavy Chain in Acute Myeloid Leukemia
Liu, P., Tarlé, S. A., Hajra, A., Claxton, D. F., Marlton, P., Freedman, M., Siciliano, M. J., & Collins, F. S. (1993) · Science · doi:10.1126/science.8351518 · Cited by 732
Erickson, P., Gao, J., Chang, K., Look, T., Whisenant, E., Raimondi, S., Lasher, R., Trujillo, J., Rowley, J., & Drabkin, H. (1992) · Blood · doi:10.1182/blood.v80.7.1825.1825 · Cited by 631 · cited 6×
“3) result in formation of chimeric transcription factor proteins PML/retinoic acid receptor a chain (RARa) (12, 26), AML1/MTG8 (ETO) (15, 39, 41), DEK/CAN (68), and E2A/PBX1 (27, 49), respectively.”
BackgroundInfluentialOgawa, E., Maruyama, M., Kagoshima, H., Inuzuka, M., Lu, J., Satake, M., Shigesada, K., & Ito, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.14.6859 · Cited by 608
Miyoshi, H., Kozu, T., Shimizu, K., Enomoto, K., Maseki, N., Kaneko, Y., Kamada, N., & Ohki, M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05933.x · Cited by 498
Ogawa, E., Inuzuka, M., Maruyama, M., Satake, M., Naito-Fujimoto, M., Ito, Y., & Shigesada, K. (1993) · Virology · doi:10.1006/viro.1993.1262 · Cited by 493
Wang, S., Wang, Q., Crute, B. E., Melnikova, I. N., Keller, S. R., & Speck, N. A. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3324-3339.1993 · Cited by 435
Tanaka, T., Tanaka, K., Ogawa, S., Kurokawa, M., Mitani, K., Nishida, J., Shibata, Y., Yazaki, Y., & Hirai, H. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07008.x · Cited by 224 · cited 10×
“This method has been used in some studies (25, 67) and is rationalized by the fact, deduced from the reactant kinetic theory, that intensities of the shifted bands are approximately proportional to the amounts of nonspecific binding [in this case, binding mainly to poly(dI-dC) included in the reaction mixture] of the…”
BackgroundMethodSelf-citationMeyers, S., Downing, J. R., & Hiebert, S. W. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.10.6336-6345.1993 · Cited by 94 · cited 2×
“Both AML1 and AML1/Evi-1 possess a runt domain, which is reported to be responsible for binding to the PEBP2 (PEA2) site (35, 52).”
Background
Cited by
Transcription Factors, Normal Myeloid Development, and Leukemia
Tenen, D. G., Hromas, R., Licht, J. D., & Zhang, D.-E. (1997) · Blood · doi:10.1182/blood.v90.2.489 · Cited by 735
The biology of CML blast crisis
Calabretta, B., & Perrotti, D. (2004) · Blood · doi:10.1182/blood-2003-12-4111 · Cited by 592
The runx genes: gain or loss of function in cancer
Blyth, K., Cameron, E. R., & Neil, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1607 · Cited by 455
The oncoprotein Evi-1 represses TGF-β signalling by inhibiting Smad3
Kurokawa, M., Mitani, K., Irie, K., Matsuyama, T., Takahashi, T., Chiba, S., Yazaki, Y., Matsumoto, K., & Hirai, H. (1998) · Nature · doi:10.1038/27945 · Cited by 371
Self-citationTurner, J. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5129 · Cited by 317
The t(12;21) Translocation Converts AML-1B from an Activator to a Repressor of Transcription
Hiebert, S. W., Sun, W., Nathan Davis, J., Golub, T., Shurtleff, S., Buijs, A., Downing, J. R., Grosveld, G., Roussel, M. F., Gary Gilliland, D., et al. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.4.1349 · Cited by 272
The AML1/ETO fusion protein activates transcription of BCL-2
Klampfer, L., Zhang, J., Zelenetz, A. O., Uchida, H., & Nimer, S. D. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14059 · Cited by 182
Ito, Y. (1999) · Genes to Cells · doi:10.1046/j.1365-2443.1999.00298.x · Cited by 179
Tanaka, T., Kurokawa, M., Ueki, K., Tanaka, K., Imai, Y., Mitani, K., Okazaki, K., Sagata, N., Yazaki, Y., Shibata, Y., et al. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.7.3967 · Cited by 152
Self-citationZhang, Y.-W., Bae, S.-C., Huang, G., Fu, Y.-X., Lu, J., Ahn, M.-Y., Kanno, Y., Kanno, T., & Ito, Y. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.7.4133 · Cited by 77
Tanaka, K., Tanaka, T., Kurokawa, M., Imai, Y., Ogawa, S., Mitani, K., Yazaki, Y., & Hirai, H. (1998) · Blood · doi:10.1182/blood.v91.5.1688 · Cited by 48
Self-citation
Metadata
- Authors
- Tanaka, T., Mitani, K., Kurokawa, M., Ogawa, S., Tanaka, K., Nishida, J., Yazaki, Y., Shibata, Y., & Hirai, H.
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 1995-05-01
- Volume
- 15
- Issue
- 5
- Pages
- 2383-2392
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- OpenAlex
- W2171915984
- Cited by
- 101
- References
- 9
- FWCI
- 5.14
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.